Clinical Research Directory
Browse clinical research sites, groups, and studies.
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
Sponsor: Yonsei University
Summary
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.
Official title: Drug-Coated Stent Versus Drug-Eluting Stent for One-month Dual-antiplatelet Therapy in Patients With Acute Coronary Syndrome: ONE-PASS Trial
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3520
Start Date
2022-08-10
Completion Date
2030-02-14
Last Updated
2025-05-21
Healthy Volunteers
No
Conditions
Interventions
Drug-coated stent
The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
Drug-eluting stent
The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
Locations (1)
Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea